Abstract
The appearance of cognitive decline as a major hallmark of neurological and neurodegenerative disorders make it an intriguing pathophysiological
state for which there is an urgent need for the development of effective pharmacotherapy. Decades of research have uncovered a multitude of
promising factors that can serve as the starting point for research and development in this domain of research. Depleted cholinergic
neurotransmission and oxidative damage are two such causative factors for cognitive impairment associated with neurodegeneration. Approved
treatments for neurodegenerative disorders like Alzheimer's Disease (AD) provide only symptomatic relief and are known to cause unwanted side
effects. Honeybee products are made up of bioactive substances, which have long been known for their medicinal and health-promoting effects.
The purpose of the present study was to explore the neuroprotective potential of bee venom and bee propolis separately and in combination with the
standard drug rivastigmine as a novel treatment regimen against scopolamine-induced cognitive decits. Intraperitoneal administration of bee
venom (0.5 mg/Kg), propolis (250 mg/Kg, oral) and rivastigmine (0.5 mg/Kg) or their combinations showed improved cognitive functions in
scopolamine exposed mice as assessed by passive avoidance test. Administration of honeybee products (venom and propolis) alone and in
combination signicantly decreased the activity of acetylcholinesterase in the brain of scopolamine treated animals. Bee products either alone or in
combination further decreased the lipid peroxidation with a concomitant increase in the activity of antioxidant enzymes (SOD, catalase, GPx, GR,
and GST) in the brains of the animals treated with scopolamine. The data obtained suggests that the treatment with combination of bee venom and
propolis could be developed into a novel and effective therapy against cognitive dementia associated with neurological and neurodegenerative
disorders including Alzheimer's disease.
Subject
General Computer Science,Human-Computer Interaction,Philosophy,Electrical and Electronic Engineering,Control and Systems Engineering,Social Psychology,Sociology and Political Science,Environmental Science (miscellaneous),Geography, Planning and Development,General Social Sciences,General Economics, Econometrics and Finance,Sociology and Political Science,Social Sciences (miscellaneous),Education,Information Systems and Management,Computer Science Applications,Software,Artificial Intelligence,Computer Graphics and Computer-Aided Design,Computer Networks and Communications,Software,Artificial Intelligence,Computer Graphics and Computer-Aided Design,Computer Networks and Communications,Computer Science Applications,Software,General Engineering
Reference58 articles.
1. Greig, N.H., et al., A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Current medical research and opinion, 2001. 17(3): p. 159-165.
2. Yu, S.Y., et al., Correlations of apathy with clinical symptoms of Alzheimer's disease and olfactory dysfunctions: a cross-sectional study. BMC Neurol, 2020. 20(1): p. 416.
3. Patterson, C., World Alzheimer Report 2018. The State of the Art of Dementia Research: New Frontiers, 2018.
4. Bentley, P., Effects of cholinesterase inhibition on brain function. 2011, UCL (University College London).
5. Colovic, M.B., et al., Acetylcholinesterase inhibitors: pharmacology and toxicology. Current neuropharmacology, 2013. 11(3): p. 315-335.